HARMONY BIOSCIENCES HOLDINGS, INC. Operating Income
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Operating Income of $89.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. operating income (loss) for the quarter ending 2026-06-30 was $89.32M, a 85.38% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. operating income (loss) for the quarter ending 2026-03-31 was $37.29M, a 33.70% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. operating income (loss) for the quarter ending 2025-12-31 was $38.56M, a 30.81% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. operating income (loss) for the quarter ending 2025-09-30 was $65.49M, a 6.12% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. operating income (loss) for fiscal 2025 was $208.47M, a 9.25% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. operating income (loss) for fiscal 2024 was $190.83M, a 0.63% decline from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. operating income (loss) for fiscal 2023 was $192.03M, a 59.78% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. operating income (loss) for fiscal 2022 was $120.19M, a 37.31% increase from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $89.32M 10-Q · filed 2026-08-04 | $126.61M 10-Q · filed 2026-08-04 | $165.16M derived: sum of 3 quarters · filed 2026-08-04 | $230.65M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $37.29M 10-Q · filed 2026-05-07 | $75.85M derived: sum of 2 quarters · filed 2026-05-07 | $141.34M derived: sum of 3 quarters · filed 2026-05-07 | $189.51M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $38.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $104.04M derived: sum of 2 quarters · filed 2026-02-24 | $152.22M derived: sum of 3 quarters · filed 2026-08-04 | $208.47M 10-K · filed 2026-02-24 |
| 2025-09-30 | $65.49M 10-Q · filed 2025-11-04 | $113.67M derived: sum of 2 quarters · filed 2026-08-04 | $169.91M 10-Q · filed 2025-11-04 | $225.64M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $48.18M 10-Q · filed 2026-08-04 | $104.42M 10-Q · filed 2026-08-04 | $160.15M derived: sum of 3 quarters · filed 2026-08-04 | $221.86M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $56.24M 10-Q · filed 2026-05-07 | $111.97M derived: sum of 2 quarters · filed 2026-05-07 | $173.68M derived: sum of 3 quarters · filed 2026-05-07 | $195.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $55.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $117.44M derived: sum of 2 quarters · filed 2026-02-24 | $138.79M derived: sum of 3 quarters · filed 2026-02-24 | $190.83M 10-K · filed 2026-02-24 |
| 2024-09-30 | $61.71M 10-Q · filed 2025-11-04 | $83.07M derived: sum of 2 quarters · filed 2025-11-04 | $135.10M 10-Q · filed 2025-11-04 | $175.29M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $21.36M 10-Q · filed 2025-08-05 | $73.39M 10-Q · filed 2025-08-05 | $113.58M derived: sum of 3 quarters · filed 2026-02-24 | $178.09M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $52.03M 10-Q · filed 2025-05-06 | $92.23M derived: sum of 2 quarters · filed 2026-02-24 | $156.74M derived: sum of 3 quarters · filed 2026-02-24 | $203.64M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $40.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $104.70M derived: sum of 2 quarters · filed 2026-02-24 | $151.61M derived: sum of 3 quarters · filed 2026-02-24 | $192.03M 10-K · filed 2026-02-24 |
| 2023-09-30 | $64.51M 10-Q · filed 2024-10-29 | $111.41M derived: sum of 2 quarters · filed 2024-10-29 | $151.83M 10-Q · filed 2024-10-29 | $199.45M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $46.90M 10-Q · filed 2024-08-06 | $87.33M 10-Q · filed 2024-08-06 | $134.94M derived: sum of 3 quarters · filed 2025-02-25 | $146.84M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $40.42M 10-Q · filed 2024-04-30 | $88.04M derived: sum of 2 quarters · filed 2025-02-25 | $99.94M derived: sum of 3 quarters · filed 2025-02-25 | $133.05M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $47.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $59.51M derived: sum of 2 quarters · filed 2025-02-25 | $92.63M derived: sum of 3 quarters · filed 2025-02-25 | $120.19M 10-K · filed 2025-02-25 |
| 2022-09-30 | $11.90M 10-Q · filed 2023-10-31 | $45.02M derived: sum of 2 quarters · filed 2023-10-31 | $72.57M 10-Q · filed 2023-10-31 | $101.20M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $33.12M 10-Q · filed 2023-08-01 | $60.67M 10-Q · filed 2023-08-01 | $89.30M derived: sum of 3 quarters · filed 2024-02-22 | $110.36M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $27.56M 10-Q · filed 2023-05-02 | $56.19M derived: sum of 2 quarters · filed 2024-02-22 | $77.24M derived: sum of 3 quarters · filed 2024-02-22 | $100.55M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $28.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $49.68M derived: sum of 2 quarters · filed 2024-02-22 | $73.00M derived: sum of 3 quarters · filed 2024-02-22 | $87.53M 10-K · filed 2024-02-22 |
| 2021-09-30 | $21.05M 10-Q · filed 2022-11-01 | $44.37M derived: sum of 2 quarters · filed 2022-11-01 | $58.90M 10-Q · filed 2022-11-01 | $66.66M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $23.31M 10-Q · filed 2022-08-02 | $37.84M 10-Q · filed 2022-08-02 | $45.60M derived: sum of 3 quarters · filed 2023-02-21 | $55.98M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $14.53M 10-Q · filed 2022-05-03 | $22.29M derived: sum of 2 quarters · filed 2023-02-21 | $32.67M derived: sum of 3 quarters · filed 2023-02-21 | $39.98M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $7.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $18.14M derived: sum of 2 quarters · filed 2023-02-21 | $25.45M derived: sum of 3 quarters · filed 2023-02-21 | $16.99M 10-K · filed 2023-02-21 |
| 2020-09-30 | $10.38M 10-Q · filed 2021-11-09 | $17.69M derived: sum of 2 quarters · filed 2021-11-09 | $9.23M 10-Q · filed 2021-11-09 | -$25.61M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $7.31M 10-Q · filed 2021-08-10 | -$1.15M 10-Q · filed 2021-08-10 | -$35.99M derived: sum of 3 quarters · filed 2022-02-28 | -$65.80M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$9.61M 10-Q · filed 2021-05-11 | -$43.30M derived: sum of 2 quarters · filed 2022-02-28 | -$73.11M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$33.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$63.50M derived: sum of 2 quarters · filed 2022-02-28 | -$145.90M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$29.80M 10-Q · filed 2020-11-12 | -$112.21M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |